Get the Daily Brief
Latest Biotech News
PepGen hit with partial hold — U.S. sites paused, global program continues
The FDA placed a partial clinical hold on PepGen’s Freedom2‑DM1 Phase II study after re‑examining preclinical toxicology data, pausing U.S. enrollment while permitting work to continue in other...
Illumina expands alliance: Adds 50,000 genomes with paired proteomics
Illumina said it will add 50,000 whole genomes paired with proteomic profiles to the Alliance for Genomic Discovery (AGD), with pharmaceutical partners GSK and Amgen leading the proteomics...
Tenaya taps Alnylam in $1.13B target pact — RNAi joins cardiac discovery
Tenaya Therapeutics signed a discovery collaboration with Alnylam Pharmaceuticals that provides $10 million up front and up to $1.13 billion in milestone payments if up to 15 delivered genetic...
Evo 2: AI model designs genomes across the tree of life
Researchers published Evo 2, a foundation DNA model trained on genomes from over 100,000 species, and demonstrated the model’s ability to identify disease‑causing mutations and design...
Liquid biopsy goes systemic: cfDNA fragmentomics detects liver disease
Johns Hopkins and collaborators expanded cell‑free DNA fragmentomics beyond oncology, showing fragment‑level cfDNA patterns can detect liver fibrosis and cirrhosis and flag chronic disease...
Atavistik raises $160M to push allosteric drugs for blood disorders
Atavistik Bio extended its Series B financing by $40 million, bringing total Series B proceeds to $160 million to support clinical trials of allosteric therapies for hereditary hemorrhagic...
Gene regulation therapy cuts seizures in Dravet: unprecedented clinical results
A gene regulation approach for Dravet syndrome, zorevunersen, produced dramatic seizure reductions and functional gains in pediatric patients in early clinical testing, according to data published...
Moderna to pay up to $2.25B — ends LNP patent saga
Moderna agreed to a settlement that could total up to $2.25 billion with Roivant/Genevant and Arbutus over lipid nanoparticle (LNP) technology used in its COVID-19 vaccines. The deal includes a...
FDA places partial hold on PepGen’s DM1 study: regulators probe preclinical data
The U.S. Food and Drug Administration placed a partial clinical hold on PepGen’s Freedom2‑DM1 phase II multiple‑ascending‑dose trial for myotonic dystrophy type 1 (DM1), citing concerns about...
Illumina expands pharma alliance: adds 50,000 genomes with paired proteomics
Illumina announced it will add 50,000 whole genomes with paired proteomic data to the Alliance for Genomic Discovery (AGD) dataset, with pharmaceutical members GSK and Amgen leading the expansion....
Roche pledges ₩710B to South Korea — builds global clinical‑trial hub
Roche committed ₩710 billion (about $485 million) in investment to South Korea over five years to establish the country as a major global hub for clinical trials. The initiative, inked with Korean...
UCB inks $1.1B deal for Antengene’s CD19/CD3 T‑cell engager
UCB agreed to license Antengene’s ATG‑201, a CD19×CD3 bispecific T‑cell engager (TCE), in a deal that includes $80 million upfront and more than $1.1 billion in potential development and...
Tenaya, Alnylam sign $1.13B cardio discovery pact: $10M up front
Tenaya Therapeutics and Alnylam Pharmaceuticals struck a discovery collaboration under which Tenaya will deliver up to 15 novel genetic targets for Alnylam to develop as RNAi therapeutics. Alnylam...
Atavistik raises $40M extension — Series B totals $160M to fund HHT trial
Atavistik Bio added $40 million in a Series B extension, bringing the round’s total to $160 million to support clinical testing of its lead program for hereditary hemorrhagic telangiectasia (HHT)....
Cognito raises $105M Series C to advance Spectris into pivotal study
Cognito Therapeutics closed a $105 million Series C round to advance its Spectris non‑invasive neurostimulation platform through a pivotal HOPE study in Alzheimer’s disease and to prepare for...
Gene therapy cuts seizures in Dravet: single‑gene approach posts large gains
A gene‑targeting therapy, zorevunersen, delivered marked seizure reductions in children with Dravet syndrome in clinical studies led by University College London and Great Ormond Street Hospital....
AI fragmentomics flags liver fibrosis and cirrhosis from blood
Johns Hopkins researchers and collaborators demonstrated a prototype liquid biopsy that uses genome‑wide cell‑free DNA (cfDNA) fragmentation patterns and AI to detect liver fibrosis and cirrhosis....
Illumina expands pharma research alliance: adds 50,000 genomes with proteomics
Illumina announced it will add 50,000 whole genomes paired with proteomic profiles to the Alliance for Genomic Discovery (AGD), with GSK and Amgen leading the expansion and DeCode Genetics...
Zealand posts Phase 2 win: amylin analog yields up to 10.7% mean
Zealand Pharma released Phase 2 data for petrelintide, an amylin analog that drew one of the industry’s largest obesity partnerships last year. The company reported mean weight reductions up to...
Lilly offers employer program — study finds GLP‑1 weight regain plateaus below baseline
Eli Lilly launched a program aimed at expanding employer coverage of GLP‑1 obesity medicines while new meta‑analysis data show weight regain after GLP‑1 receptor agonists tends to plateau below...